Financial Planning for Urologists in Australia

Urologists hold specialist registration under AHPRA (approximately $900–$1,000 per year for specialist practitioners in 2024–25). Fellows of the Urological Society of Australia and New Zealand (USANZ) pay annual membership fees typically in the range of $1,000–$2,500 depending on member category. Subspecialty society memberships - the Urological Oncology Society of Australasia (UOSA) or paediatric urology groups - carry additional annual fees that are deductible if directly related to professional competency.

AHPRA registration and USANZ fellowship fees are fully deductible as professional expenses in the year of payment. CPD costs required to maintain USANZ fellowship - conferences, robotic surgery training, simulation courses, and hands-on workshops - are also deductible.

Urology MDO premiums are stratified by the complexity and risk profile of procedures performed. Urologists performing predominantly endoscopic and minimally invasive procedures - cystoscopy, TURP, URS (ureteroscopy), ESWL, flexible cystoscopy - sit in a lower-risk MDO tier. Premiums for endoscopic-predominant urologists typically range from $15,000–$35,000 per year.

Robotic-assisted urological surgery has transformed the MDO landscape for Australian urologists. Robotic radical prostatectomy (RALP), robotic nephrectomy, robotic-assisted radical cystectomy, and robotic pyeloplasty carry higher per-procedure risk - particularly for intraoperative and delayed vascular complications, ureteric injuries, and oncological margin adequacy in cancer resection. Urologists performing high-volume robotic oncological surgery may see premiums in the $35,000–$70,000 range.

Oncological urology - radical cystectomy with urinary diversion, radical nephrectomy for RCC, retroperitoneal lymph node dissection (RPLND) for testicular cancer, and open radical prostatectomy - carries the highest exposure in urological practice. Complex urinary diversion (ileal conduit, neobladder) and RPLND involve significant complication risk including bowel injury, vascular injury, and functional reconstruction failure. Oncological urologists performing complex reconstructive work may see premiums at the upper end of the specialty range.

Paediatric urology carries extended limitation period exposure - claims relating to paediatric procedures do not begin the limitation clock until the patient reaches adulthood (age 18). Urologists performing paediatric hypospadias repair, vesicoureteric reflux surgery, and paediatric oncological urology need to account for this extended tail period in their run-off planning.

Annual MDO declaration requires accurate disclosure of procedure volumes by type - endoscopic, laparoscopic, robotic, open, and oncological. Undisclosed addition of higher-risk procedures or robotic surgery to a practice scope creates policy voidance risk at claim.

Urologists in Australia typically combine public VMO sessional appointments with private procedural and consultation practice. VMO sessional income from a public hospital is employment income (PAYG); private procedural fees and consultation income are professional income subject to PSI analysis.

Prostate cancer management - TRUS biopsy, MRI-targeted fusion biopsy, radical prostatectomy, and ongoing PSA surveillance - constitutes a significant portion of urological income in private practice. High-volume robotic prostatectomy practices generate substantial procedural income, with significant private out-of-pocket costs for complex oncological surgery. Informed financial consent documentation is mandatory for all elective private procedures.

Telehealth and rural urology outreach generate distinct income streams. Telehealth consultation income is professional income (PSI if channelled through a company). Rural procedural income from visiting specialist services may be subject to different Medicare billing item codes and incentive payments - confirm accurate MBS item use for rural procedural visits.

Urologists operating through a company or trust are subject to PSI rules. Surgical fees, consultation income, and procedural income all derive from the urologist's personal professional skills - they are PSI and must be attributed personally for tax purposes.

VMO sessional payments from a public hospital are employment income (PAYG) and cannot be rerouted through a company. Private procedural and consultation income channelled through a company is PSI unless the practice genuinely employs other urologists whose independent billings exceed 50% of practice revenue.

Robotic surgery platform costs - da Vinci system maintenance, instrument costs, and theatre access fees paid to the private hospital - are costs incurred by the hospital, not a PSI diversion mechanism. Urologists who hold equity in a private hospital or day surgery facility may receive investment returns from that equity; the income characterisation depends on the ownership structure.

Urological training typically involves 5–6 years of vocational training post-internship, often followed by 1–2 years of subspecialty fellowship (robotic surgery, oncological urology, endourology, or paediatric urology). The total path from medical graduation to independent private practice is typically 13–16 years.

Division 293 tax applies an additional 15% on concessional contributions when income plus concessional contributions exceeds $250,000. Established urologists - particularly those with high-volume robotic oncological practices - will commonly exceed this threshold. Concessional contributions remain tax-effective above the threshold if marginal rates exceed 30%.

The carry-forward concessional contribution rule allows urologists with total super balances under $500,000 at the prior 30 June to access up to 5 years of unused concessional cap space - up to $137,500 in a single year. This is most valuable in the first high-income consultant years after the training period.

An SMSF becomes cost-competitive for most urologists once total super balances exceed $300,000–$400,000, typically within 5–8 years of consultant practice. Consulting rooms or specialist centre premises purchased through an SMSF via an LRBA at arm's-length market rent provide the standard SMSF commercial property benefit.

The ATO safe harbour LRBA interest rate for real property in 2024–25 is 8.85% per annum. Robotic surgery equipment (da Vinci system) held by a private hospital in which a urologist holds equity is not eligible for direct SMSF investment - medical equipment leased to a related party breaches the 5% in-house asset limit.

From 1 July 2025, Division 296 applies an additional 15% on notional SMSF earnings attributable to balances above $3 million. Urologists with high contribution rates across a long career should model projected super balances and consider supplementing with non-super investment structures as the $3 million threshold approaches.

Roopon members access exclusive discounts on health insurance, financial planning, and professional memberships across Australia. Join today for FREE included prize-draw entries per your plan and published campaign terms. See /giveaways for live prizes.

Review these items each financial year:

• Confirm AHPRA and USANZ fees are claimed as deductions in the correct year
• Update MDO annual declaration with accurate procedure volumes by type - endoscopic, laparoscopic, robotic, open oncological, paediatric
• Notify MDO when adding robotic-assisted procedures - undisclosed scope changes create policy voidance risk at claim
• Model run-off obligations for paediatric urological work - limitation periods do not start until age 18; build a dedicated run-off reserve
• Document informed financial consent for all elective private procedures including complex oncological surgery
• Run PSI tests on all income streams - separate VMO sessional (PAYG) from private procedural and consultation income (PSI through company)
• Assess Division 293 liability before setting salary sacrifice levels ($250,000 income + concessional contributions threshold)
• Check carry-forward concessional contribution availability - up to $137.5k catch-up if super balance under $500k at 30 June
• Confirm SMSF LRBA interest rate against ATO safe harbour (8.85% for real property 2024–25)
• Model projected super balance against Division 296 $3M threshold - supplement with non-super investment structures if approaching

A specialist medical accountant familiar with urological surgery's robotic procedure costs, oncological practice income structure, and paediatric run-off complexity will provide planning that a generalist cannot replicate.